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Members of a large family of Ankyrin Repeat Domains proteins (ANKRD) regulate 
numerous cellular processes by binding and changing properties of specific protein targets. 
We show that interactions with a target protein and the functional outcomes can be markedly 
altered by cells’ metabolic state. ANKRD9 facilitates degradation of inosine monophosphate 
dehydrogenase 2 (IMPDH2), the rate-limiting enzyme in GTP biosynthesis. Under basal 
conditions ANKRD9 is largely segregated from the cytosolic IMPDH2 by binding to 
vesicles. Upon nutrient limitation, ANKRD9 loses association with vesicles and assembles 
with IMPDH2 into rod-like structures, in which IMPDH2 is stable. Inhibition of IMPDH2 
with Ribavirin favors ANKRD9 binding to rods. The IMPDH2/ANKRD9 assembly is 
reversed by guanosine, which restores association of ANKRD9 with vesicles.  The conserved 
Cys109Cys110 motif in ANKRD9 is required for the vesicles-to-rods transition as well as 
binding and regulation of IMPDH2. ANKRD9 knockdown increases IMPDH2 levels and 
prevents formation of IMPDH2 rods upon nutrient limitation.  Thus, the status of guanosine 
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Chapter 1: Introduction 
Section 1.1: Ankyrin Repeat domain containing proteins 
Introduction to ANKRD9 and ankyrin domain-containing (ANKRD) proteins 
 ANKRD9 (ankyrin-domain containing protein 9) is a 35 kDa protein with at least one 
predicted ankyrin repeat. Typically, ankyrin repeats are involved in protein-protein 
interactions which are essential for a variety of cellular processes. While there are around 60 
ANKRD proteins that are small, soluble adapter proteins, the majority of ankyrin repeats 
exist as a domain of several repeats within a larger protein.  This chapter describes the types 
of repeats found in proteins (Section 1.1.1),  the discovery and structure of ankyrin repeats 
(Section 1.1.2) and finally a selection of proteins that contain ankyrin repeats (Section 1.1.3). 
These examples illustrate the importance of generating a surface for protein-protein 
interaction and put into context the relationship between ANKRD9 and its partner IMPDH2, 
described in Section 1.2. In our studies we have shown that ANKRD9 stabilizes IMPDH2 
macro-assembly in the form of rods and that this structure may serve to protect IMPDH2 




























Figure 1: Repeats found in different proteins. On the top  left is -catenin (PDB 1JDH (1)) 
with each color representing an armadillo repeat, a close-up view is shown on the bottom 
left. On the top right is Toll-like Receptor 3 (PDB 2A0Z (2)) with each color representing a 
leucine rich repeat, a close- up view is shown on the bottom. Ankyrin repeats rank among 








Section 1.1.1: Types of structural repeats in proteins  
Ankyrin domains are among the most used repeats in proteins 
Tandem repeats in proteins are widespread with several appearing most often. These 
include ankyrin repeats, leucine rich sequences, and tetratricopeptide, armadillo and HEAT 
repeats (3). These repeats are described as follows: leucine-rich repeats make for a greasy, 
hydrophobic surface; tetratricopeptide and armadillo repeats each form a superhelical 
structure or solenoid and  HEAT (Huntingin-elongation factor 3 (EF3), protein phosphatase 
2A (PP2A) subunit, PI3-kinase TOR1) repeats form short, flexible helices (3,4) (Figure 1). 
Ankyrin repeats (AR) are usually around 30-34 amino acids long and consist of both 
hydrophobic and hydrophilic residues. Proteins containing several AR (as many as 24 repeats 
can be present) typically form curved solenoid structures and participate in processes ranging 
from cell cycle regulation to signaling.  The association of AR-containing proteins with 
inherited and sporadic disease underscores their importance and need to be explored (5-8). A 
common thread throughout these repeats is the significance of secondary structure. Many of 
the primary ‘consensus’ sequences for these repeats are guidelines to the secondary fold 
rather than indicators of absolute sequence requirement. For example: hydrophobic residues 
have been replaced for more hydrophilic residues to have better access to solvent (3). 
Although the repeats in proteins are widespread, oftentimes their function is not fully 
understood. 
Uniqueness of ankyrin repeats compared to others 
Ankyrin repeats are unique in several aspects. In addition to proteins containing 
several ankyrin repeats as a well-defined part of their structure, there are over 60 ‘orphan’ 





A role in autophagy has been described for ANKRD49 and a role in membrane binding and 
cardiac function has been described for ANKRD1 (9,10). Additionally, while other repeats 
participate mainly in protein-protein interaction, ankyrin repeats have been recently shown to 
mediate binding of proteins to lipids and sugars as well as small molecules as in TRPV4, 
described in Section 1.1.3 (3,11). Lastly, most of the repeats discussed earlier in this chapter 
are composed of alpha helices only and can pack to form higher order solenoid structures. 
Ankyrin repeats form a helix-turn-helix structure where as many as 24 repeats can stack to 
form a surface for protein-protein interactions, as observed in the human ankyrin protein 
(12). These features make ankyrin repeats versatile and somewhat elusive in determining 
their exact function in a given cellular state.  
 
Section 1.1.2.  The discovery and structure of ankyrin repeats 
The helix-turn-helix nature of ankyrin repeats forms a concave structure 
Ankyrin repeats find their history from yeast and fly studies. The repeat was 
discovered as part of the cell cycle complex Swi6/Cdc10 in yeast as well as in Drosophila 
protein Notch (3,5). Human ankyrin was then shown to have homology to the Drosophila 
protein and to contain 24 ankyrin repeats. The structure of 12 ankyrin repeat stacks (repeats 
13-24) from human ankyrin was determined and revealed the presence of a membrane 
binding domain, spectrin binding domain and a death domain (12). Additionally, the 
structure identified a consensus sequence Threonine-Proline-Leucine-Histidine (TPLH) that 
marks the beginning of the first alpha helix of the repeat that occurs in every repeat in this 



















Figure 2:  Ankyrin repeats in human Ankyrin. A 12 ankyrin stack is depicted on the left and a  
close-up view on the right. Each color on the left depicts one ankyrin repeat.  The TPLH 
motif is boxed and is as follows. T:yellow, P: magenta, L:orange, H: cyan. Adapted from, 

















 The threonine residue identifies the beginning of both the alpha helix and the start of 
an ankyrin repeat (12).  These residues were conserved in the 12 repeats solved in this 
structure. The secondary structure also revealed a so-called ‘ankyrin groove’ which has since 
been defined as the first alpha helix and -hairpin of a single repeat, forming an L-shape 
(12). Several ankyrin repeats together (Figure 2) form a concave structure with the helices on 
the outside and the -hairpin turns on the inside. Within one repeat, stability is afforded by a 
group of small non-polar residues making up the alpha helices where longer range contacts 
are made by a hydrogen bond network which partially consists of aromatic residues between 
the helices.  Smaller, flexible residues such as glycine and alanine also make up this region to 
allow for the turns. The presence of more than one repeat in ankyrin proteins could be 
explained by the observation that one repeat in solution does not properly fold unless another 
repeat is present (13).  
 
Binding of ankyrin repeats to other proteins 
ANKRDs bind ankyrin repeats in other proteins primarily through the concave fold 
discussed above. The repeats may modulate catalytic activity, mediate interactions between 
proteins, increase protein stability, regulate protein expression and targeting and can even be 
used for drug targeting (14-19). The structures of ankyrin repeats from several proteins have 
been solved; these structures provide direct evidence for protein-protein interactions at the 
alpha helices that make up the backbone of the repeats (20-22). Additionally, software has 





repeats (23). Interestingly, while much of the interactions occur on the helix folds, the beta 
hairpin loops were shown to function as dimerization domains (24).  In our work described in 
Chapter 2 interactions between ANKRD9 and IMPDH2 occurred specifically in the loop 
regions of ANKRD9. 
 
Section 1.1.3: Important ankyrin repeat containing proteins 
TRPV channels contain ankyrin repeats involved in disease and small molecule binding 
Ankyrin repeats do not typically recognize a particular set of residues (6). Rather, 
their stacking generates a platform upon which proteins bind and carry out essential 
functions. This emphasis on secondary structure is especially important when considering the 
function of proteins that contain these repeats. In addition to the cytoskeletal ankyrin itself, 
the most well-known proteins that contain ankyrin repeats are the Transient Receptor 
Potential channels or TRPV (11,25,26). These cation channels have several subfamilies 
including TRPA channels, whose intracellular domain consists of several ankyrin repeats 
(25). These channels respond to a variety of stimuli including stress, cell swelling, heat and 
to certain chemicals like arachidonic acid and ligands like 4-phorbol-12,13-didecanoate 
(11). Mutations in these channels can lead to many diseases, including Charcot-Marie-Tooth 
disease, with some mutations occurring within the ankyrin repeats of these proteins (11,25).  
Studies examining channel activity have found that the ankyrin repeats modulate 
many properties including channel sensitivity. In fact, it was shown that an ankyrin repeat 
within TRPV4 directly and specifically binds phosphatidylinositol-4,5-bisphosphate 
(PI(4,5)P2) which then blocks channel activity; gain-of-function mutations specifically 





studies where ATP was also shown to bind to the ankyrin repeats of TRPV4.  This binding 
stabilized the ankyrin fold and also modulated channel activity (25,26). The ankyrin repeat 
serves to significantly modulate channel activity of TRPV4 owing to its large surface for 
protein-protein interactions. It is also interesting that ATP binding stabilizes the ankyrin fold, 
indicating that one metabolite may regulate these types of repeats. In Chapter 2 we show that 
GTP may regulate the macromolecular assembly of ANKRD9. 
Bcl-3 is a signaling protein whose ankyrin repeats aid in NF-B function 
Another important ankyrin-domain containing protein is Bcl-3, which is involved in 
NF-B signaling. NF-B is a transcription factor whose translocation to the nucleus is 
inhibited by IB, or inhibitor of NF-B, which masks NF-B’s nuclear localization signal 
(27). Bcl-3 is a member of the IB family but is nucleoplasmic and serves as a co-activator 
once NF-B signaling pathways are activated to allow translocation to the nucleus (28). Both 
Bcl-3 and IB  have ankyrin repeats, so it was intriguing that they essentially carried out 
opposing functions. The crystal structure of the ankyrin domain of  Bcl-3 revealed that a 
seventh ankyrin repeat was present in Bcl-3 (there are 6 in IB) and several residues in this 
repeat could not bind the nuclear localization signal of NF-B like IB could (27). In 
addition, Bcl-3 forms a stable complex with DNA whereas IB cannot, owing to an exposed 
basic surface in the seventh Bcl-3 ankyrin repeat as revealed by modeling studies (27). This 
example shows that ankyrin repeats can influence entire cell signaling networks, and the 
mere presence of ankyrin repeats in  two different proteins does not necessarily translate to 








Tankyrase contains ankyrin repeats responsible for substrate binding 
Tankyrase 1(PARP5A or ARTD5) and 2,  are enzymes involved in the addition of 
ADP-ribosyl moieties to target proteins. Tankyrase 1 and 2 belong to the poly (ADP-ribose) 
polymerase (PARP) enzymes (29). Addition of ADP-ribose has several consequences 
including subsequent ubiquitylation and degradation, however when a single ADP-ribose is 
added other signaling consequences ensue. What is unique about these proteins is that 
Tankyrase 1 and 2 in particular have 24 ankyrin repeats called the ankyrin repeat cluster or 
ARC in addition to a catalytic site and several other domains (29).  For Tankyrase 1, several 
of its ankyrin repeats are responsible for substrate binding to allow the PARP enzymatic 
domain to add the ADP-ribose modification to its target. One such substrate is AXIN which 
is involved in the WNT signaling pathway where Tankyrase 1 binds AXIN through 
ARC2,4,5 and 1 which also causes Tankyrase 1 dimerization (29). This is important as it 
shows how ankyrin repeats can influence conformation. In Chapter 2 we describe how 
ANKRD9 binds to and stabilizes IMPDH2 rod macroassembly. 
Tankyrase also has roles in telomere extension. Tankyrase-mediated  ADP-
ribosylation of  TRF1(telomeric repeat binding factor 1) prevents it from blocking access to 
the telomere. Furthermore, Tankyrase is involved in insulin-dependent glucose uptake (30). It 
has been recently shown that in skeletal muscle Tankyrase 1 inhibition or downregulation is 
associated with a decrease in abundance of several glucose transporters including insulin-
responsive GLUT4.  Reversal of the Tankyrase effect on GLUT4 stability was achieved by 
blocking the proteasome (30). This example shows that ankyrin repeats can be responsible 






Phospholipases have diverse functions and contain ankyrin repeats involved in 
oligomerization 
Phospholipases A2 comprise an additional family of ankyrin-containing proteins (31-
33). Specifically, iPLA2 has 8 ankyrin repeats that are involved in the oligomer formation 
and activity of this enzyme (32). iPLA2 is a calcium independent phospholipase A, which 
has lysophospholipase activity.  In addition to the ankyrin repeats, iPLA2 has a nucleotide 
binding motif, an N-terminal caspase-3 site and a nuclear localization sequence (33). The 
ankyrin repeats have been shown to influence oligomeric formation where iPLA2 subunits 
interact via their ankyrin repeats. In fact, the enzyme with ankyrin repeat mutations was 
reported inactive (32). Additionally the nucleotide binding region of iPLA2 has been shown 
to bind ATP, similar to  the TRPV4 channel, and this binding promotes stabilization of 
oligomer (34). That oligomeric formation requires ankyrin repeats points to their extensive 
involvement in varied and complex protein-protein interactions where structure informs 
function. Interestingly, ankyrin repeats are only found in this specific phospholipase. Other 
phospholipases, including iPLA2, which is implicated in mitochondrial function and fat 
utilization, and iPLA2, which plays a role in triacylglyceride deposition, do not have ankyrin 
repeats(33).These phospholipases have not been shown to oligomerize which may be the 
reason why they do not contain ankyrin repeats.  
 iPLA2 is involved in a host of processes, including membrane remodeling, cell 
proliferation, bone formation and male fertility (33,35,36). A common theme through these 
seemingly disparate processes is the products of iPLA2 enzymatic activity, which are 





lysophospholipid acceptors generated as products are proposed to help arachidonic acid 
integration into phospholipids for eventual incorporation into the phospholipid bilayer (33).  
During cell proliferation again the iPLA2 products are proposed as responsible for 
activating the transcription of certain genes for cell division.  Overall, ankyrin repeats not 
only provide necessary surfaces for protein-protein interaction but also are required for 
activity. This  underscores the need for multiple ankyrin repeats to carry out different 
activities and ankyrin containing proteins typically have several repeats.  
 
Conclusions on ankyrin domain containing proteins 
The above examples of important classes of proteins containing ankyrin repeats 
highlight protein-protein interactions as the main driver of varied repeat functions from pain 
sensing channels to NF-B signaling to phospholipase activity. While there is some 
conservation in the sequence of these repeats, it is their secondary structure that dictates 
function. Throughout evolution many residues have been replaced for more favorable ones, 
yet the overall fold has been preserved. Additionally, these different classes highlight the 
importance of multiple (up to 24 ) repeats. A single repeat alone is generally unfolded and 
lacks its characteristic helix-hairpin-helix structure (13).  
In addition to proteins that have ankyrin repeats as a part of the structure, there are 
small proteins composed of ankyrin repeats alone without enzymatic activity. The function 
and mechanism behind their cellular activities are often not well understood. Indeed, ankyrin 
domain containing proteins such as ANKRD9 studied here may not have enzymatic activity 
or multiple different domains but instead are utilized by other proteins lacking ankyrin 





spatially or temporally. Also, association with one ankyrin domain containing protein or 
another could be useful under different circumstances.  
 
Section 1.1.4: ANKRD9 identification and roles 
ANKRD9 has several varied roles  
ANKRD9, or ankyrin-domain containing protein 9, is a small 35 kDa protein with one 
reported ankyrin repeat occurring at residues 32-203, however according to the consensus 
sequence described in Section 1.1.2 the ankyrin repeat occurs at amino acid residues 195-
216. Additionally, the secondary structure, shown in Figure 10a, consists of mostly helix-
turn-helix repeats which is the ankyrin fold so there may be more although they may not have 
the canonical sequence. A  structural model of ANKRD9 shows that the protein is made up 
of helix-hairpin-helices (see Figure 10a in Chapter 2, Section 2.3). ANKRD9 is predicted to 
have 5 splice variants and 4 exons; all splice variants encode the ANKRD9 protein. 
ANKRD9 expression is ubiquitous in most tissues, with slightly elevated expression in 
skeletal muscle and the colon 
(https://www.genecards.org/cgibin/carddisp.pl?gene=ANKRD9&keywords=ANKRD9), it is 
not known whether isoforms are expressed in different tissues. ANKRD9 is one of at least 60 
ankyrin-domain containing proteins where roles have only been assigned to a few of them, 
including ANKRD49 with a reported role in autophagy (9).  
 
ANKRD9’s role in copper homeostasis 
 In our laboratory ANKRD9 was initially discovered as a regulator of copper 





in HeLa cells using siRNA and cellular metal levels were analyzed by ICP-MS (inductively 
coupled plasma mass spectrometry) to determine metal content changes. Nine elements were 
tested, including selenium, copper, phosphorus, magnesium, potassium, cadmium, 
manganese, iron and zinc. Normalization and secondary screens narrowed the list to genes 
that altered copper levels to a significant degree. ANKRD9 knockdown in HeLa cells 
increased copper levels specifically and significantly (37). ANKRD9 had a z-score of 7.18, 
which was similar to z-score of protein with well-established roles in copper metabolism.  
Further experiments confirmed the role of ANKRD9 in regulation of copper uptake and 
possible role in glycosylation of important copper proteins CTR1 and ATP7A (see (38,39) 
for a review of both proteins), but the mechanism remains under investigation.  
.  
ANKRD9’s role in lipid metabolism 
There are three additional papers concerning the role of ANKRD9. The first 
published study implicated ANKRD9 in lipid metabolism in the chicken (40). Authors 
initially  compared sequences of ANKRD9 in human, mouse, chicken and zebrafish; 
compared to human ANKRD9 there is 85%, 70% and 63% sequence identity, respectively. 
Additional characterization identified that ANKRD9  was most similar to the ankyrin binding 
domain of  Calcium independent phospholipase A2,  discussed in Section 1.1.3. ANKRD9 
has no signal peptide or transmembrane domain. While the human ANKRD9 is 317 amino 
acids and 35 kDa the chicken ANKRD9 is 292 amino acids and 32 kDa and is expressed in 
the heart, muscle, brain and liver. A single ankyrin repeat was also identified from the 





To investigate the role of ANKRD9 in lipid metabolism authors used a riboflavin-
deficient strain of chicken (rd/rd). Fatty acid oxidation (FAO) requires riboflavin as a 
cofactor for acyl-CoA dehydrogenase in the first step where Palmitoyl-CoA is converted to 
trans-2- Enoyl-CoA and eventually Acetyl Co-A; embryonic development in the chicken 
uses FAO.  Consequences of riboflavin deficiency include lipid accumulation, increases in 
genes promoting lipid storage such as PPAR and adipophilin as well as loss of carbohydrate 
reserves; the riboflavin deficient strain is a model for lipid metabolic perturbations.  
At embryonic day 13 in rd/rd chickens ANKRD9 mRNA levels were increased by 
about 30-fold. This suggests that higher lipid content occurring with riboflavin deficiency 
contributes to higher ANKRD9 levels; chickens past embryonic day 13 without riboflavin do 
not survive. Adding thyroid hormone (T3)  to the diet, which decreases body fat and 
triglyceride content and is similar to reversing the riboflavin-deficient effect, decreased 
ANKRD9 mRNA levels. This is consistent with the idea that higher lipid content increases 
ANKRD9 levels. 
 To further explore the metabolic changes associated with fluctuating ANKRD9 
levels the authors used a fasting-refeeding model. In this model, normal animals were either 
fully fed, fasted for 16, 24 and 48 hours or fed for 24 hours following a 48 hour fast. They 
found that ANKRD9 mRNA levels increased about 7-fold in the last scenario, i.e. upon 
feeding after fasting. As refeeding is similar to having a lowered amount of fatty acid 
oxidation, which occurs in the riboflavin-deficient model, this upregulation of ANKRD9 
suggests that it plays a specific role in regulating fatty acid oxidation.  The authors lastly 







ANKRD9’s role as an IMPDH2 partner protein 
The second report on the function of ANKRD9 is a proteomics study into the 
interactome within a cell. Authors mapped the human interactome of HEK293 cells using  
high throughput affinity purification of 13,000 FLAG-HA tagged open reading frames 
followed by mass spectrometry (41). They found interacting partners for 2,594 proteins. 
IMPDH2 (inosine monophosphate dehydrogenase 2), described in Section 1.2, was used as 
bait and ANKRD9 was found as one its interacting partners. Other proteins found to interact 
include with IMPDH2 were IMPDH1, PUSL1 (pseudouridylate synthase-like 1), SRP2 (S 
phase Kinase associated protein) and SMCR8 (Smith-Magenis syndrome chromosome region 
candidate 8). That ANKRD9 was found as a partner protein for a nucleotide biosynthesis 
enzyme further shows that ankyrin repeats can take on a variety of important roles.  
 
ANKRD9’s role in cell proliferation and interaction with IMPDH2 
The third report explores the interaction between ANKRD9 and IMPDH2 in the 
context of cell proliferation and cancer (42). Authors suggest that ANKRD9 is a part of a 
ubiquitin-ligase complex that targets IMPDH2 . They describe the subunits of a CUL-5 
(cullin-5) ubiquitin ligase (E3) complex which includes a scaffold, adaptor, RING domain 
binding to E2 and substrate receptor. The authors propose that ANKRD9 serves as the 
substrate receptor where IMPDH2 is the substrate for ubiquitination and degradation. 
To arrive at this conclusion, ANKRD9 was initially identified as a cancer associated 
gene in this report. Cancer patients and controls were genotyped for 13 ANKRD9 single 





previous reports showed that ANKRD9’s expression was reduced in gastric cancer (43). 
FLAG-tagged ANKRD9 was then used to show that overexpression of ANKRD9 reduced  
proliferation of human MKN45 cancer cells while ANKRD9 knockdown increased 
proliferation.  
ANKRD9 was then identified as having a SOCS (suppressor of cytokine signaling) 
box which is typical of substrate receptor proteins in ubiquitin ligase complexes. It has also 
been shown that Asb11 (ankyrin repeats and SOCS box 11) is a member of ubiquitin ligase 
complex (44).  SOCS-box containing proteins can bind other subunits of CUL-5 ubiquitin 
ligase complexes; the authors showed that ANKRD9 binds to ELOB-C and CUL5 with co-
transfection of the ANKRD9 SOCS box and ELOB (elongin-B) and ELOC (elongin-C). The 
authors therefore concluded here that ANKR9D is an ASB (ankyrin repeats and SOCS box, 
described above). 
The authors lastly explored ANKRD9’s relationship with IMPDH2 as it was 
identified from Co-IP mass spectrometry experiments with FLAG-ANKRD9 as bait. They 
found that ANKRD9 specifically contributes to IMPDH2 degradation through the ubiquitin-
ligase complex where ANKRD9 overexpression lowered IMPDH2 levels and its knockdown 
increased IMPDH2 levels. Additionally, ANKRD9’s function in cells depended on IMPDH2; 
overexpressing IMPDH2 reduced ANKRD9’s impact on cell proliferation. These findings 
show co-dependence of ANKRD9 and IMPDH2 and point to a specific role of ANKRD9 in 
cancer cell proliferation. The authors did not, however, show the definitive role of ANKRD9, 
however, only that it is associated with cell proliferation by lowering IMPDH2 protein levels.  
They suggest that since IMPDH2 is overexpressed in cancer cells, ANKRD9 may serve to 





These reports point to varied functions of ANKRD9 in cell physiology but so far 
there is no definitive connection between ANKRD9 roles in  lipid metabolism, copper 
metabolism, and nucleotide metabolism . Our studies into the interaction between ANKRD9 
and IMPDH2 provide a first look at the spatiotemporal control of ANKRD9 owing to its 























Section 1.2: Inosine monophosphate dehydrogenases 
Section 1.2.1: IMPDH2 and nucleotide metabolism 
IMPDH2 is the rate-limiting enzyme for guanine nucleotide biosynthesis  
Inosine monophosphate dehydrogenase 2 (IMPDH2) is the rate-limiting enzyme in 
guanine nucleotide biosynthesis (45,46). It catalyzes the conversion of inosine 
monophosphate (IMP) to xanthine monophosphate which is then converted to guanine 
monophosphate by guanosine monophosphate synthase and finally to guanosine triphosphate 
through nucleoside diphosphate kinases (46,47). This process constitutes the purine de novo 
pathway for generating guanosine triphosphate, GTP. The salvage pathway uses guanosine, 
which is converted to guanine by purine nucleoside phosphorylase. Prior to the action of 
IMPDH2 there are several steps which begin with PRPP, or phosphoribosyl pyrophosphate, 
which is the precursor to all purine nucleotides (48), see Figure 3.  
IMP can be diverted to ATP synthesis in the de novo pathway if it is converted to 
adenosine monophosphate by adenylosuccinate synthetase and adenylosuccinate lyase (49). 
The steps that convert PRPP to IMP use the metabolite glutamine (48,50). For pyrimidine 
biosynthesis carbamoyl phosphate is converted to uridine triphosphate. CTPS1/2 (cytidine 
triphosphate synthetase) then converts  UTP to CTP (51). CTPS2 is an important enzyme in 
nucleotide biosynthesis with  cellular behavior similar to IMPDH2, described in Section 
1.2.2. Guanosine triphosphate is used for DNA/RNA synthesis, glycoprotein synthesis and 














Figure 3: Guanine nucleotide synthesis pathway. The de novo pathway (left) uses IMPDH2 
to convert IMP to XMP and finally to GDP which is then used for DNA/RNA synthesis as 
well as glycoprotein synthesis. The salvage pathway (right) uses precursor guanosine to 
generate GTP. Abbreviations: ASL: adenosylosuccinate lyase, AMP: adenine 
monophosphate, IMP: inosine monophosphate, PRPP: phosphoribosyl pyrophosphate, 
IMPDH2: Inosine monophosphate dehydrogenase 2, XMP: xanthine monophosphate, GMP 










Section 1.2.2: Macromolecular assembly 
IMPDH2 has a nucleotide-binding regulatory domain  
IMPDH2 is a 55 kDa protein with an active site for catalysis and a regulatory domain. 
Sister enzyme IMPDH1 has 84% sequence identity; IMPDH2 is overexpressed in rapidly 
proliferating cells (52). The active site contains adjacent substrate (IMP) and cofactor 
(NAD+, nicotinamide adenine dinucleotide) sites (45-47). The regulatory domain consists of 
two cystathionine -synthase (CBS) domains which bind nucleotides to regulate IMPDH2 
activity (53,54). In IMPDH2, ATP and GTP bind to activate or inactivate IMPDH2, 
respectively (54,55). Specifically, ATP stabilizes the IMPDH2 homotetratmer in an open 
conformation whereas GTP stabilizes the IMPDH2 homotetratmer in a closed conformation 
(56,57).  
 
In vitro and cellular rod formation  
An interesting phenomenon that occurs with IMPDH2 in cells is the formation of rods 
and rings (RR), also termed cytoophidia, meaning ‘snakes’ (48,58-62). This occurs under two 
circumstances, in vitro and in cells without much consensus in the field on whether the 
structures formed under either of these circumstances are related. The addition of ATP to 
purified IMPDH2 yields fibrils around 200 nanometers in length, which can be visualized 
using electron microscopy (63). These are known as higher order oligomers of IMPDH2 
tetramers, and whether or not these are active has been an open subject. Some studies report 
that purified IMPDH2 rods are active as they are formed with ATP and show increases in 





In cells, IMPDH2 forms rods and rings that are 3-5 microns long under a variety of 
circumstances. Amino acid starvation, T cell activation, and inhibition using Ribavirin, 
Mycophenolic Acid and DHFR (dihydrofolate reductase) inhibitors have been reported as 
triggers of IMPDH2 rod formation in cells;  IMPDH rods also occur naturally in some stem 
cell lines (48,60,64-66). Mycophenolic acid has been reported to lower IMPDH2 activity and 
it is proposed that inhibitors lower GTP pools (62,67). Recently rods and rings have been 
reported in mouse tissue following administration of Ribavirin, a substrate inhibitor used as 
an antiviral (68). Rod formation is conserved throughout evolution, with rods seen in 
Drosophila, S.pombe, S.cerevisea and human cell lines (66,69,70). They have been shown to 
form perinuclearly and over time, with time-lapse microscopy showing an increase in rod 
length over 2 hours after Mycophenolic Acid treatment (64).  
 
Rod reversal and the importance of guanosine  
So far, the only known metabolite that reverses rod formation in cells is the addition 
of guanosine; conversion to guanine occurs with purine nucleoside phosphorylase found in 
FBS (fetal bovine serum) in complete medium (67). Explanations for guanosine-mediated 
disassembly of IMPDH2 rods include having an excess of this final product.(62,67). That 
Ribavirin, substrate inhibitor of IMPDH2 and rod formation trigger, has its effect reversed by 
guanosine supports this idea. However, the fact that GTP binds to the regulatory domain of 
IMPDH2 and forces a closed inactive conformation has not been reconciled with the 
observation that guanosine reverses rod formation; it is possible that reversal of IMPDH2 











Figure 4: IMPDH2 dimer, PDB 1NF7. In red and blue are CBS domains 1 and 2 which bind 
nucleotides. CTPS2 binds nucleotides but does not contain CBS domains, which in Chapter 2 
















Rod formation also occurs with related enzyme CTPS2 but responds differently to 
nucleotides 
Rod formation has been reported for other metabolic enzymes including CTPS2, 
which forms rods following inhibition by DON (6-diazo-5-oxo-L-norleucine) (59,71). It has 
been shown that formation of rods by human CTPS2 enhances catalytic activity whereas 
bacterial CTPS2 rod formation lowers activity, further compounding the rod formation 
phenomenon (72,73). Two reports investigated IMPDH2/CTPS2 rod formation together. The 
first concluded that IMPDH2 and CTPS2 rods were generally separated. DON specifically 
converts CTPS2 into rods without affecting IMPDH2, whereas Ribavirin triggers appearance 
of both  IMPDH2 and CTPS2 rods (61). The second report concluded that IMPDH2 and 
CTPS2 have interfilament interactions (74). Of note, CTPS2 rods are generally longer than 
IMPDH2 rods (70). 
Nucleotide binding consequences are different for the enzymes. It has been found that 
while GTP inhibits IMPDH2 and disassembles rods, it enhances CTPS2 activity, perhaps to 
balance purine and pyrimidine synthesis (72). In addition, ATP, UTP and CTP have been 
shown to influence tetramerization of CTPS2, whereas IMPDH2  oligomerizes with ATP 
addition and disassembles with GTP addition (note that this oligomerization is with purified 
CTPS2 and IMPDH2) (73).  Also while IMPDH2 has canonical CBS domains described 
above (and shown in Figure 4) for nucleotide binding, CTPS2 does not have CBS domains 
but does have putative nucleotide binding sites, as reported for E.coli CTP synthase and 





 Thus, while both IMPDH2 and CTPS2 can form rods, IMPDH2 has specific 
requirements for doing so where CTPS2 has many more factors that influence its 
oligomerization. CTPS2 can assemble and disassemble in response to a variety of 
metabolites but IMPDH2 can only do so with the ATP/GTP pair, primarily owing to the 
canonical CBS domains which are not present in CTPS2. These differences in CTPS2 and 
IMPDH2 responses to regulator molecules provides further evidence for the specificity of the 
ANKRD9-IMPDH2 interaction that we observed in our work (see Chapter 2). 
 
Why rods are formed is an open question   
Explanations for rod formation include: a storage depot, to enhance or inhibit 
catalytic activity, and as simple aggregates without specific function (66,70,75).  For 
example, one model posits that CTPS2 forms oligomeric rods that are inactive whereas the 
homotetramer is active (70).  Recently another enzyme -asparagine synthetase- has been 
reported to form rods with AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an 
analog of AMP that stimulates AMPK activity  (76). While more enzymes have been added 
to the growing list of proteins capable of forming rods, protein lacking enzymatic activity 
have not been reported to form rods. Our studies provide a first such example in the case of 
ANKRD9 and investigate functional significance.   
Section 1.2.3: IMPDH2 and ANKRD9 
ANKRD9 was identified as part of a ubiquitin ligase complex  where IMPDH2 was 
the substrate for degradation  (described in Section 1.1.4) (41,42). While this report was the 
first to describe the potential role of the ANKRD9-IMPDH2 interaction (a prior proteomics 
screen identified IMPDH2 and ANKRD9 as partner proteins) we address how ANKRD9 





Our studies show that ANKRD9 indeed forms rods which co-localize with IMPDH2 
rods in response to nutrient deprivation and IMPDH2 inhibition with Ribavirin. We also 
show that guanosine reverses ANKRD9/IMPDH2 rods and identify residues for ANKRD9 
rod formation and ANKRD9/IMPDH2 interaction. This work supports the idea that 
ANKRD9 stabilizes IMPDH2 under certain metabolic conditions in the form of rods. 
Importantly, rod formation could be used to protect IMPDH2 from ANKRD9-dependent 
degradation, which may occur through the CUL-5 ubiquitin ligase described in the previous 
report. Another model supporting this theory is that IMPDH2 rods are inactive to keep from 
degradation (66). Also of note is the observation that rod formation does not occur with 
IMPDH2 CBS domain deletion (54), which fits with our data as ANKRD9 and IMPDH2 
interact within the CBS domains in the vicinity of the IMPDH2 nucleotide binding site (see 
Figure 12 in Chapter 2, Section 3.2). This work shows that an  ankyrin-domain containing 
protein is  capable of forming rods under specific metabolic conditions where rod reversal  is 























Chapter 2: ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance 
and macro-assembly 
Modified from: Hayward et. al. ANKRD9 is a metabolically-controlled regulator of IMPDH2 














Chapter 2: ANKRD9 is a metabolically-controlled regulator of IMPDH2 abundance 
and assembly 
Section 2.1: Introduction 
Ankyrin Repeat Domain proteins (ANKRD) form a large and fascinating family of 
proteins that regulate numerous cellular proteins and pathways. The activities of ANKRDs 
involve protein complex assembly, interactions with the cytoskeleton, post-translational 
modifications, regulation of protein degradation and many others (3,5,7,9,11,13,25,27). 
Structural basis of interactions between ANKRDs and their targets is becoming clearer (3), 
however little is known about regulation of these interactions in cells. In some cases, the 
same ANKRD binds to different protein targets and modulates distinct cellular pathways, 
these different forms of action remain poorly understood. 
ANKRD9 (ankyrin-domain containing protein 9) is an ankyrin-domain containing 
protein implicated in a broad spectrum of cellular processes, including lipid metabolism (40), 
copper homeostasis (37) and cell proliferation (42). Recent genome-wide association studies 
have uncovered the potential role of ANKRD9 in hypertension (77) and myocardial 
repolarization(78). Despite the accumulating evidence of ANKRD9’s physiologic and 
clinical significance, information about functional properties and mechanisms of ANKRD9 
are very limited. Analysis of the protein sequence predicted ANKRD9 to be a 35 kDa protein 
with at least one ankyrin repeat. In a large mass-spectrometry screen of the human 
interactome, ANKRD9 was co-purified with inosine monophosphoate dehydrogenase 2 
(IMPDH2) (41), the rate limiting enzyme in GTP biosynthetic pathway. Recent studies 





levels by stimulating interactions with the ubiquitin-ligase complex and causing protein 
degradation (42). 
These findings are difficult to reconcile with the original report, which demonstrated 
that in cells ANKRD9 was targeted to vesicle-like structures (40) and could therefore be 
spatially separated from IMPDH2, which is a cystolic enzyme. ANKRD9 mRNA levels are 
under nutritional control (40) and therefore it is possible that the ANKRD9 protein has 
different localization and functions under different metabolic conditions. Our studies have 
tested this hypothesis. We have found that the intracellular location of ANKRD9 and its 
regulation of IMPDH2 depend on availability of metabolites (guanosine) as well as a tertiary 
structure of IMPDH2. Taken together, our results suggest a mechanism through which 
ANKRD9 modulates the intracellular properties of IMPDH2 in response to metabolic 
changes.  
Section 2.2: Results 
In cells, ANKRD9 adopts two distinct forms. 
This work started with an observation that expression of a FLAG-tagged ANKRD9 in 
HeLa cells produced two very different intracellular patterns. In the majority of cells, 
ANKRD9 was associated with vesicles (Fig. 4a), in agreement with a previous report (40), 
whereas in some cells ANKRD9 was present in distinct 3-5 microns “rod-like” structures 
(Fig. 5a, arrows).  While vesicles were numerous and distributed throughout the cell, 
typically only few (1-3 per cell) rods were formed in the cytoplasm and around the nucleus.  
The appearance of the rods was intriguing, because IMPDH2 (an established target of 
ANKRD9) is known to assemble into rod-like filaments (also called cytoophidia) in response 






















 Figure 5: ANKRD9 adopts two distinct forms (a) HeLa cells were transfected with FLAG-
ANKRD9 expressing plasmid and immuno-stained for the FLAG-tag. FLAG-ANKRD9 (red) 
shows a vesicular and rod-like pattern (gray arrows); cell nuclei are visualized with DAPI 
(blue); n=3. (b) Inosine monophosphate dehydrogenase 2 (IMPDH2) forms rods when 
inhibited with Ribavirin. HeLa cells were treated with 10 μM Ribavirin for 1hr then stained 
for IMPDH2 green) and DAPI (blue); n=2. (c) IMPDH2 mediates the rate limiting step 
(conversion of inosine monophosphate, IMP, to xanthine monophosphate, XMP) in a 
pathway beginning with phosphoribosyl pyrophosphate (PRPP) and eventually leading to 
guanosine triphosphate, GTP. IMPDH2 transitions from a diffuse cytosolic form (left) to rods 
(right) when inhibited with Ribavirin; this transition is reversed with guanosine. (d) HeLa 
cells were treated with 10 M Ribavirin for 1 hour then transfected with FLAG-ANKRD9 
for 16hrs and immuno-stained for FLAG (green) and IMPDH2 (red). Gray arrows point to 













 Formation of IMPDH2 rods can be rapidly induced by incubating cells with 
Ribavirin, a potent cell-permeable inhibitor of IMPDH2 (Fig. 5b,c). Consequently, to test 
whether the recombinant ANKRD9 associates with IMPDH2 in rods, we treated cells with 
Ribavirin for 1 h prior to ANKRD9 expression. Under these conditions, ANKRD9 co-
localized with the IMPDH2 rods and was also detected in vesicles in the  same cells (Fig. 
5d).  The overlap between ANKRD9 and IMPDH2 in rods was complete, i.e. no ANKRD9-
rods without IMPDH2 was detected.  Thus, in addition to the “basal” vesicular form, 
ANKRD9 interacts with the inactive IMPDH2 in rod-like filaments. 
 
ANKRD9 forms rods upon nutrient limitation 
These results were interesting because they demonstrated the previously unknown 
ability of ANKRD9 to assemble with IMPDH2 in large macromolecular complexes. To 
better understand the physiologic basis of ANKRD9/IMPDH2 assembly we considered that 
ANKRD9 mRNA levels respond to starving/re-feeding (i.e. are nutrient dependent (40)) and 
that IMPDH2 forms rods when cells are starved of certain metabolites (48,65).  
Consequently, we tested whether nutrient deprivation would cause transition of ANKRD9 
from vesicles to rods. Cells transfected with ANKRD9 plasmid were grown in low serum 
(0.1% FBS) for 24 and 48 hours and stained for ANKRD9 and IMPDH2.  After 48 hours of 
nutrient limitation all ANKRD9 was found in rods (compare Fig 6a and 6b).  The transition 
from vesicles to rods was time dependent (Fig. 6c); i.e. after a shorter nutrient limitation - 24 






























Figure 6: ANKRD9 forms rods upon nutrient depletion. HeLa cells were transfected with 
FLAG-ANKRD9 (red) as in Fig 5a and incubated in the presence of 10%FBS (a) or 0.1% 
FBS (b) for 48 hrs. Rods are indicated by gray arrows; nuclei are stained with DAPI (blue); 
n=3 (c) Percentage of cells containing ANKRD9 in vesicles (black) or rods (grey) after 
overnight transfection (control), followed by 24 hrs or 48 hours in starvation (0.1% FBS) 
media. Total number of analyzed cells: n=137 (control); 149 (24h), and 131 (48h); Error bars 
represent standard error. Two-way ANOVA was used to determine p-values (*, p value = 
0.03, ****, p value < 0.0001) (d) Representative images of each timepoints; rods appear in 



















Formation of ANKRD9 rods is caused by depletion of IMPDH2 dependent metabolites. 
Brief treatment of cells with Ribavirin and a prolonged nutrient depletion both cause 
IMPDH2 inhibition and the ANKRD9/IMPDH2 assembly.  In the first case, the vesicle-to-
rod transition of ANKRD9 was partial, whereas in the second case it was complete.  One 
important difference between these two conditions is the duration of IMPDH2 inactivation.  
Partial effect of brief treatment with Ribavirin suggested that the inhibition of IMPDH2 per 
se could be insufficient for ANKRD9 dissociation from vesicles and that the depletion of 
IMPDH2-dependent metabolite(s) may be needed for complete conversion of ANKRD9 into 
a rod-bound form.  To test this hypothesis, we added Ribavirin to cells prior to ANKRD9 
expression, as previously, and then allowed cells to grow for 24 and 48 hours under basal 
conditions (i.e. in normal serum) in the presence of Ribavirin (Fig. 7).   
After 24 hours, ANRKD9 fully transitioned to rods (Fig. 7b).  The rods contained 
both ANKRD9 and IMPDH2 and were very similar to those induced by 48 hours of nutrient 
limitation (compare Fig. 7a and Fig. 7b).  The result suggests that the prolonged incubation 
with the IMPDH2 inhibitor mimics serum starvation conditions, i.e. the treatment depletes 












Figure 7: Formation of ANKRD9 rods is caused by depletion of IMPDH2 metabolites (a) 
HeLa cells were transfected with FLAG-ANKRD9 then placed in 0.1% FBS for 48 hours and 
immunostained for FLAG and IMPDH2; n = 3 (b) HeLa cells were treated with 10 M 
Ribavirin for 1 hour then transfected with FLAG-ANKRD9 and kept in 10% FBS for 24 and 
48 hours. Cells were immunostained with anti-FLAG (red) and anti-IMPDH2 (green) 
antibodies; n=2. Merged images show complete overlap between ANKRD9 and IMPDH2 







Guanosine reverses the ANKRD9 relocalization from vesicles to rods 
To test further whether the vesicle-to-rod transition of ANKRD9 represents a 
regulatory response to metabolic state of the cell, we tested whether the ANKRD9 transition 
to rods can be reversed.  First, cells were grown under nutrient limiting conditions for 24 
hours to induce rod formation, then washed and placed into the basal growth medium for 24 
hours.  This treatment decreased the abundance of rods and caused appearance of vesicles, 
but did not fully restore ANKRD9 targeting to vesicles (Fig 8). We then considered that the 
depletion of guanine pools was previously suggested to cause IMPDH2 macro-assembly and 
that IMPDH2 rods can be disassembled by guanosine addition (62,67).  
Consequently, we tested whether the ANKRD9/IMPDH2 rods, formed under 
conditions of nutrient limitation, were affected by guanosine. To this end, we expressed 
FLAG-ANKRD9, induced rod formation by incubating cells for 48 hrs in low serum and 
then added 100 M guanosine for 1hr (this concentration was previously shown to reverse 
IMPDH2 rod formation (Fig. 9, (67)).  Addition of guanosine completely reversed the 
ANKRD9 assembly with IMPDH2 and caused uniform transition of ANKRD9 back to 
vesicles (compare Fig. 9a and 9b). This effect was rapid; the vesicular pattern of ANKRD9 
was already observed at 10 minutes following addition of guanosine (Fig. 9c). Thus, the 
disassembly of ANKRD9 occurs on a much faster timescale than rod formation, perhaps 
reflecting addition of a large excess of guanosine. Guanosine-dependent change in ANKRD9 
pattern also suggests that cellular behavior of ANKRD9 may be controlled by the same 










Figure 8: Serum re-addition partially reverses rod formation in ANKRD9. HeLa cells were 
transfected with FLAG-tagged ANKRD9 and incubated under nutrient limiting conditions 
(0.1% FBS) for 24 hours, then cell growth medium was replaced with the medium containing 
10% FBS. Cells were incubated for another 24 hours and then immunostained for FLAG. 
Both (a) and (b) are representative images of cells after the above conditions. The 24 hours 
nutrient limitation induces ANKRD9 transition from vesicles to rods in approximately 50% 
of cells (see Figure 6). Placing cells in 10% serum for 24 hours only partially reverses this 
phenotype i.e some cells still have ANKRD9 in rods (long and short) and other cells show 













Figure 9: ANKRD9 transition to rods is reversible with guanosine addition (a) Control: 
FLAG-ANKRD9 forms rods following incubation of HeLa cells in 0.1% FBS for 48hrs; (b) 
The same treatment, followed by incubation with 100 M guanosine for 1hr. The ANKRD9 
rods disappear and ANKRD9 shows a vesicular pattern; (c) Percentage of cells with 
ANKRD9 vesicles or rods at 10 and 60 min following addition of guanosine. The number of 
ANKRD9 rods at 10 and 60 min was compared using unpaired t test. n=3 for each time 
point; Error bars represent SEM. ****, p value <0.0001. Scale bar: 20 m. 





Purified IMPDH2 can assemble into rods in vitro in the absence of any other proteins 
(54,55,63,66,70,80). Therefore, the role of ANKRD9 in IMPDH2 rods is likely to be 
regulatory and involve modulation of rods’ properties. It was previously shown that IMPDH2 
rods were dynamic and could change their length over time. Consequently, to clarify the 
functional significance of ANKRD9/IMPDH2 macro-assembly, we compared the length and 
numbers of IMPDH2 rods in cell with endogenous and overexpressed ANKRD9 under 
conditions of nutrient limitation. Ribavirin treatment was used as a control for rod formation. 
In nutrient-depleted HeLa cells (that have endogenous ANKRD9), the length of IMPDH2 
rods was about 1.5 microns, whereas in HeLa cells overexpressing FLAG-ANKRD9 the 
length of IMPDH2 rods was significantly increased to 3-5 microns (Fig. 10a,b). Note that 
ANKRD9 endogenous levels in HeLa cells are very low, HEK293A cells were used in 
knockdown experiments to determine ANKRD9’s role.  
The length of IMPDH2/ANKRD9 rods is similar to IMPDH2 rods formed in the 
presence of Ribavirin (Fig 10c). This result further suggests that under conditions of nutrient 
limitation ANRKD9 binds to an inhibited IMPDH2. An increased length of IMPDH2 rods 
suggested that excess ANKRD9 stabilizes the IMPDH2 rods favoring longer structures. 
Indeed, we found that without ANKRD9 overexpression the number of IMPDH2 rods per 
cell was about 6, whereas significant increase in rods length upon ANKRD9 overexpression 

















Figure 10: Higher ANRKD9 abundance is associated with longer IMPDH2 rods.  (a) 
Control: immunostaining of IMPDH2 in HeLa cells under basal conditions shows an 
expected diffuse pattern (left panel). Treatment of these cells with 10 M Ribavirin for 1 hour 
in the absence of recombinant ANKRD9 triggers formation of IMPDH2 rods (right panel). 
(b) Left panel: In the absence of recombinant ANKRD9, nutrient limitation (0.1 % FBS for 
48 hours) causes appearance of short IMPDH2 rods. Right panel: Expression of 
recombinant FLAG-ANKRD9 significantly increases the length of IMPDH2 rods (c) 
Quantitation of IMPDH2 rod length in different treatment conditions (d) Quantitation of 
number per cell under nutrient limitation in the absence and presence of recombinant 
ANKRD9. Excess ANKRD9 favors formation of longer and fewer IMPDH2 rods. Number of 
cells: treatment with Ribavirin (n = 150), nutrient limitation (n =73) of non-transfected cells. 
For nutrient limitation with FLAG-ANKRD9 expression, n = 156. Statistical analysis of data 
was done using an unpaired t test, ****, p , 0.001. Error bars represent standard error. 
















A conserved CysCys motif is required for ANKRD9 vesicle-to-rod transition 
ANKRD9 has not been characterized biochemically and its structure is unknown.  
Consequently, to better understand the biochemical basis of ANKRD9/IMPDH2 interactions, 
we predicted the structure of ANKRD9 using the Robetta server (Fig. 11a).  The molecular 
model of ANKRD9 shows nine helix-turn-helix repeats assembled into a concaved structure. 
To identify amino-acid residues important for ANKRD9 function, we searched for highly 
conserved residues that are located at protein surface and therefore available for protein-
protein interaction. ANKRD9 is highly conserved, but the sequence alignment of ANKRD9 
orthologs from multiple species identified several invariant residues in the loop regions of 
ANKRD9 (Fig. 11a).  Two conserved vicinal cysteines Cys109Cys110 (Fig. 11b) were of 
particular interest, because cysteines are susceptible to various modifications and hence can 
contribute to observed changes in ANKRD9 intracellular behavior.  
To directly test the role of Cys109Cys110 motif in rod formation we generated a series 
of mutants, in which Cys109 and Cys110 were converted to serine individually or together. The 
C109S, C110S and C109S/C110S mutants were expressed in HeLa cells and their ability to 
form rods was analyzed under nutrient-limiting conditions. Unlike WT ANKRD9, which 
shows complete transition to rods after 48 hrs in 0.1% FBS, none of the mutants lost 
association with vesicles and formed rods under these conditions (Figure 11c). This result 
suggests that while Cys109 and Cys110 do not play an important role in ANKRD9 binding to 















Figure 11: A conserved CysCys motif in ANKRD9 is required for vesicle to rod transition (a) 
Structural model of the entire ANKRD9 protein with conserved Cys residues highlighted in 
blue; the boxed area shows the position of Cys109 and Cys110 in the loop (b) Multiple 
sequence alignment of the CysCys-containing region illustrates conservation of this motif. (c) 
HeLa cells transfected with WT ANKRD9 (control) or indicated ANKRD9 mutants were 
placed in 0.1% FBS-containing medium for 48 hours. Unlike WT, none of the mutants 














CysCys motif contributes to ANKRD9-IMPDH2 interaction  
The observed inability of Cys109Cys110 mutants to leave vesicles and form rods may 
reflect the role of this motif in “sensing” the metabolite depletion. To determine whether the 
Cys residues were involved in binding and regulation of IMPDH2, we first explored the 
possible structural interactions between ANKRD9 and IMPDH2 by docking our Robetta 
model and the known crystal structure of IMPDH2 (Figure 12a, left panel). The docking 
revealed favorable interactions between the ANKRD9 loop containing the  Cys109Cys110 
motif with the regulatory domain of IMPDH2 (Fig. 12a, right panel), near the reported 
nucleotide binding site of IMPDH2 (Fig 13 (54)).  
To directly verify these interactions and their consequences, we took advantage of the 
report that appeared when this work was on-going (42). The published study suggested a role 
for elevated ANKRD9 in proteasome-mediated degradation of IMPDH2. Consequently, we 
expressed the WT ANKRD9 and ANKRD9 mutants in HeLa cells under basal conditions and 
compared their effect on IMPDH2 abundance.  Although the intracellular localization of WT 
and mutants, in vesicles, was very similar, their effects on IMPDH2 levels were drastically 
different.   
 Expression of WT ANKRD9 was associated with a marked decrease in staining of 
IMPDH2 protein, as evidenced by confocal imaging (Fig. 12b).  This effect was specific for 
IMPDH2, as overexpression of ANKRD9 did not influence levels of CTP synthase 2, CTPS2 
(Fig. 14a,(71-73,81,82) ), another metabolic enzyme known to form rod-like structures. Use 
of proteasome inhibitor MG132 after transfection with WT ANKRD9 prevented decrease of 
IMPDH2 levels (Fig. 14b) supporting the proposed role for ANKRD9 in facilitating 




















Figure 12: The Cys109 Cys110 motif contributes to ANKRD9-IMPDH2 interaction (a) Left: 
Docking model of ANKRD9 and IMPDH2 (PDB ID 1nf7) with the IMPDH2 catalytic and 
regulatory domains indicated by the arrows; the predicted interaction site is outlined by the 
box. Right: The magnified view of the predicted interaction site between ANKRD9 (orange) 
and IMPDH2 (purple). The CysCys motif in ANKRD9 interacts with K167, E168 and E169 
of IMPDH2; (b) Cys mutants do not facilitate IMPDH2 degradation. HeLa cells were 
transfected with the WT ANKRD9 and indicated mutants under basal conditions and 
immunostained for FLAG and IMPDH2. Cells expressing WTANKRD9 showed 
significantly reduced IMPDH2 staining, whereas cells with the Cys mutants did not; n=3 (c) 
Cys mutants of ANKRD9 do not form rods with IMPDH2. HeLa cells were transfected with 
the indicated constructs and subsequently treated with 10 M Ribavirin for 1hr prior to 





immuno-staining for FLAG and IMPDH2; n=3 (d) The WT and ANKRD9 mutants were 
expressed in HeLa cells and 
immunoprecipitated using Anti-FLAG M2 resin overnight. The next day the resin was 
washed and incubated with FLAG peptide at 2 mg/mL to elute. Input (10% ot total), 
















Figure 13: ANKRD9 binds IMPDH2 near nucleotide binding site.  ANKRD9 is predicted to 
bind to IMPDH2 regulatory domain in the vicinity of the GDP/GTP binding site. Regulatory 
domains of IMPDH2 dimer (PDB ID 6I0M) are shown in green and blue; GTP is in red, the 
K167/E168/E169 motif (that is predicted to interact with the ANKRD9 CysCys-containing 















Figure 14: ANKRD9 and IMPDH2 interactions are specific (a) HeLa cells were transfected 
with FLAG-ANKRD9 and immunostained for FLAG and CTPS2 under basal growth 
conditions (10%FBS). Expression of ANKRD9 does not alter CTPS2 pattern/abundance, in 
contrast to IMPDH2 (see Fig 7b), which is markedly diminished under the same conditions; 
n=2 (b) HeLa cells were transfected with FLAG-ANKRD9, treated with 10 M proteasome 
inhibitor MG132 for 4 hrs and stained for FLAG and IMPDH2. MG132 partially restores 
IMPDH2 staining in cells transfected with ANKRD9 as evidenced in insert where two out of 




















In contrast to WT ANKRD9, the C109S and C109S/C110S mutants did not 
significantly affect IMPDH2 levels (Fig 12b). Treatment with 10 M Ribavirin for 1h 
confirmed the difference in IMPDH2 abundance between cells expressing the WT and 
mutant ANKRD9s; IMPDH2 rods were absent in cells expressing WT ANKRD9 mutants 
(Figure 12c). This reflected the marked decrease in IMPDH2 abundance, and present in cells 
with C109S and C109S/C110S variants.  The effects of C110S mutant were less pronounced 
that those of the C109S, C109S/C110S variants and were closer to WT ANKRD9.  This 
result suggested that Cys109 plays the primary role in interactions with IMPDH2.  
 This conclusion was confirmed by immunoprecipitation: unlike the WT ANKRD9, 
the C109S mutant did not pull down IMPDH2 (Fig. 12d). Taken together, these results 
suggest that under basal conditions excess ANKRD9 binds to IMPDH2 and negatively 
affects its abundance.  Under condition of nutrient deprivation ANKRD9 loses ability to bind 
to vesicles, but retains ability to bind to IMPDH2 in rods. In rods, ANKRD9-dependent 
degradation of IMPDH2 is blocked, presumably by the tertiary structure of rods.  Thus, the 














ANKRD9 knockdown increases IMPDH2 levels and reduces rod formation under nutrient 
limiting conditions. 
The above experiments provided evidence for the impact of elevated ANKRD9 on 
IMPDH2. To better understand how variation in ANKRD9 abundance affects IMPDH2 we 
decreased levels of ANKRD9 in HEK293A cells using siRNA.  HEK293 cells were chosen 
because they express ANKRD9 at higher levels than HeLa cells and this allows more 
accurate measurements of siRNA-mediated down-regulation. HEK293 cells also show 
IMPDH2 assembly in rods upon serum starvation and the recombinant Flag-ANKRD9 has 
the same vesicular pattern under basal conditions as in HeLa cells (Fig. 15).    
 The siRNA-mediated knockdown reduced ANKRD9 mRNA levels by about 60% 
(Fig. 15a, upper panel); the protein levels could not be measured due to low sensitivity of 
available antibodies. The cells were then examined under basal and low serum conditions.  
ANKRD9 down regulation increased IMPDH2 expression levels (Fig. 16a, lower panel), in 
agreement with a previous report (42).  Despite upregulation, IMPDH2 did not form rods in 
response to nutrient limitation in cells with down-regulated ANKRD9 (Fig 16b). This finding 
suggests that ANKRD9 serves to stabilize IMPDH2 rods when nutrients (presumably GTP 















Figure 15: Recombinant ANKRD9 shows vesicular pattern and decreases IMPDH2 staining 
HEK293A cells were transfected with FLAG-ANKRD9 under basal conditions and 
immunostained for FLAG and IMPDH2. Cells expressing ANKRD9 (red) lack IMPDH2 












Figure 16: ANKRD9 knockdown increases IMPDH2 expression and reduces rod formation 
under nutrient limiting conditions. (a) HEK293A cells were transfected with non-targeted 
(NT) siRNA and ANKRD9 siRNA and ANKRD9 mRNA levels were quantified (top panel). 
IMPDH2 levels in corresponding cells were analyzed by western blot, -actin was used as a 
loading control (lower panels). Decrease in ANKRD9 levels is associated with higher 
IMPDH2 abundance, n =3. (b) ANKRD9 down-regulation diminishes IMPDH2 rod 
formation under nutrient limitation. HEK293A cells were transfected with the indicated 
siRNAs and stained for IMPDH2 after cells were incubated in 0.1% FBS for 48 hours. 
IMPDH2 rods were apparent in control cells, no IMPDH2 rods are visible in cells treated 
with ANKRD9 siRNA, n = 3 (c) Cartoon showing that ANKRD9 forms rods with inhibited 










Section 2.4: Discussion 
ANKRD9 is a highly conserved protein found in all vertebrates. The cellular and 
physiologic functions of ANKRD9 are poorly understood, and the limited available data 
paint a complex and confusing picture. The first report, published in 2009, found ANKRD9 
mRNA levels to be responsive to changes in lipid metabolism and nutritional availability, 
whereas the second report, published in 2018, provided evidence that ANKRD9 could be 
involved in proteasomal degradation of IMPDH2, a nucleotide processing enzyme (40,42).  
Our laboratory previously identified ANKRD9 as a novel regulator of copper homeostasis 
based on specific elevation of cellular copper in response to ANKRD9 knockdown (37). 
These ANKRD9-influenced processes have little in common; to modulate these distinct 
pathways ANKRD9 is likely to interact with more than one cellular target and these 
interactions can be spatially, temporarily, and metabolically controlled. Here we show that 
ANKRD9 has at least 2 distinct intracellular locations: vesicles and cytosolic rods (Fig. 16c).  
The presence of ANKRD9 in these locations depends on metabolic state of the cell, and has 
distinct consequences for IMPDH2 abundance and macro-assembly.  We have generated the 
molecular model for ANKRD9 and identified the cysteines residues required for changes in 
ANKRD9 intracellular localization and activity towards IMPDH2. 
 When cells are grown in low serum, ANKRD9 forms rods that overlap with IMPDH2 
rods. While low serum condition can be used to block cell cycle, we suggest that ANKRD9 
senses nutrient depletion rather than inhibition of the cell cycle progression. Our reasoning is 
the following. First, formation of rods takes longer than inhibition of cell cycle progression. 
Second, prolonged inhibition of IMPDH2 with Ribavirin accelerates formation of ANKRD9 





dependent nucleotide misbalance (compare Fig. 7a and 7b). Third, addition of guanosine 
rapidly disassembles ANKRD9 rods, suggesting that in low serum cellular guanine pools are 
lowered (Fig. 9).   
 The assembly into rods and rings is a characteristic property of IMPDH2 that has 
been extensively studied (58,59,61,62). This macro-assembly occurs in response to various 
triggers, including IMPDH2 inhibition, signaling during T-cell activation, or amino acid 
depletion.  IMPDH2 has propensity for self-assembly and no proteins with enzymatic 
functions have been found to interact with IMPDH2 rods. GTP pools are critical for IMPDH 
rods formation, since guanosine but no other nucleosides reverse the macro-assembly 
(60,62,64,67).  We found that guanosine also dis-assembles the ANKRD9/IMPDH2 complex 
and, significantly, restores ANKRD9 binding to vesicles.  This observation suggests that 
ANKRD9 may sense levels of nucleotide pools and respond by changing its 
location/association with IMPDH2. 
 GTP and ATP bind to the regulatory domain of IMPDH2 and influence not only 
macro-assembly but also IMDPH2 activity (53-55,57). In our docking model, ANKRD9 
interacts near the nucleotide-binding sites (Fig 13). This close proximity suggests that 
ANKRD9/IMPDH2 interaction in rods may influence nucleotide binding to IMPDH2, but 
this hypothesis requires further testing.   
Our experiments show that ANKRD9 binds to the inhibited IMPDH2 and increases 
the length of IMPDH2 rods. The functional significance of IMPDH2 rods has been a subject 
of significant interest and debate in the literature, since the appearance of the rods is not 
linked to either IMPDH2 abundance or activity (both active and inhibited IMPDH2 form 





cells, which may also have low surplus of nutrients. Our data suggest that under these 
circumstances macro-assembly into rods may protect IMPDH2 from ANKRD9-mediated 
degradation, which may otherwise occur when ANKRD9 loses association with vesicles in 
response to nutrient deprivation. ANKRD9 binding to IMPDH2 rods appears to stabilize 
them.  In other words, the metabolic state of the cell determines whether ANKRD9 destroys 
or protects IMPDH2. 
 CTPS2 has been shown to form rods and rings.  The CTPS2 rods are distinct from 
IMPDH2 rods although their assembly could be regulated by similar factors such as 
nucleotide metabolites (60). The previous proteome screen did not find CTPS2 among 
ANKRD9 binding partners (41) (only IMPDH1 and IMPDH2 were detected) and in our 
experiments we observed no effect of ANKRD9 on CTPS2, suggesting that the ANKRD9-
IMPDH2 assembly and regulation is specific.  
 Comparison of the predicted ANKRD9 structure to structures of other better 
characterized ANKRD-containing proteins using 3D protein Blast show that three 
dimensional fold of ANKRD9 resembles that of the ankyrin binding domain of 
phospholipase iPLA2 as well as tankyrase. The homology to the latter enzyme is 
particularly interesting.  Tankyrase mediates poly-ADP-ribosylation of various proteins, 
marking them for degradation via ubiquitin ligase pathway, and regulates mitosis, genome 
integrity, and cell signaling.  As ANKRD9, tankyrase regulates protein abundance in various 
cellular locations; -catenin in the cytosol and GLUT4 transporter in vesicles (30). It is 
tempting to speculate that coupling sensitivity to metabolites with changes in intracellular 
localization could be a common mechanistic feature of ANKRD-containing proteins with a 
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Section 2.5: Methods 
Cell lines—HeLa cells maintained in DMEM supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS),  1% Penicillin-Streptomycin and 1% non-essential amino acids and 
passaged every 2-3 days when cells were 80% confluent in T75 cm2 flasks. HEK293A cells 
were maintained in DMEM supplemented with 10% Fetal Bovine Serum, 1% Penicillin-
Streptomycin and 1% non-essential amino acids and passaged every 2-3 days when cells 
were 80% confluent in T75 cm2 flasks.  
Site-directed Mutagenesis in ANKRD9—An N-terminally labeled FLAG-tagged ANKRD9 
construct was generated from the cDNA of human ANKRD9. This construct was cloned into 
a pcDNA3.1 vector containing blasticidin and ampicillin resistance. Mutations were 
introduced using the QuikChange XL mutagenesis kit. Primers were purchased from 
Integrative DNA technologies (IDT). Presence of correct mutations and the lack of unwanted 
mutations were verified by sequencing the coding region. Primers used for mutagenesis: 
C109S forward primer: 5’-AGCCG-CGCAGCTGCGGAAGCCGG-3’; C109S reverse 
primer: 5’-CCGGCTTCCGCAGCTGCGCGGCT-3’; C110S forward primer: 5’-
GGGAGCCGCG-CTGCAGCGGAAGC-3’; C110S reverse primer: 5’-
GCTTCCGCTGCAGCGCGGCTCCC-3’; C109S C110S forward primer: 5’- GGGAGCCG-
CGCTGCTGCGGAAGCCGG-3’; C109S C110S reverse primer: 5’-
CCGGCTTCCGCAGCAG-CGCGGCTCCC-3’ 
 
Immunofluorescence Microscopy—Cells were transfected with 1 g FLAG-tagged ANKRD9 
or FLAG-tagged ANKRD9 mutants using 2% Turbofect in 200 L OPTI-MEM  in  2 mL of 





immunofluorescence as follows. HeLa cells were washed with PBS then fixed with 4% 
Formaldehyde for 15 minutes at RT. Cells were permeabilized with 0.1% Triton X-100 for 
10 minutes with mild shaking. Cells were then blocked with 1% BSA, 1% gelatin in PBS 
overnight at 4 degrees C. The next day cells were incubated with primary antibody for one 
hour at RT in a humidified chamber. Mouse anti-FLAG was used at a DF (dilution factor) of 
1:500, catalog number F1804; Millipore-Sigma, Rabbit anti-IMPDH2 was used at DF 1:300, 
catalog number ab75790; Abcam, Rabbit anti-CTPS2 was used at DF 1:300, catalog number 
ab235109; Abcam. Cells were then washed with PBS once, PBS+ 0.1% tween twice, then 
PBS, then incubated with fluorescent secondary antibody in the dark for one hour. Donkey 
anti-mouse AlexaFluor 555; catalog number A31570, Thermofisher, donkey anti-rabbit 
AlexaFluor 488, catalog number A21202, Thermofisher were used at DF 1:500. Donkey anti-
rabbit AlexaFluor 555, catalog number ab150070, abcam, was used in Figure 15b.  
Coverslips were then washed as with primary with a final wash in water to remove excess 
salts. Coverslips were then mounted with fluoromount and DAPI at 50% each. Images were 
taken with an Olympus FV3000RS confocal microscope and processed using Fiji. Images in 
Figures 7 and 13 were taken with a Zeiss LSM 5 Pascal confocal microscope and processed 
using Image J.  
 
Quantifying rod length—For rod length, images were processed as previously described (73). 
Briefly, images were deconvoluted to 8-bit and threshold was arbitrarily adjusted to 44 for all 
images. The analyze particles application was used where length below 0.5 was excluded and 





obtain rod number per cell. Ten images in random locations containing at least ten cells was 
used for quantification in each category of non-transfected versus transfected conditions.  
Structural modeling—Homology model: We used a crystal structure of protein IMPDH2 
(PDB ID 1nf7) and the Robetta model for ANKRD9. To refill all missed regions of the 
IMPDH2 structure, we created a homology model using the Molecular Operating 
Environment (MOE) software, version 2018.01 (CCG, Montreal, Canada). The full sequence 
of the protein including missed in crystal structure amino acids was used. Homology models 
were created with the Homology Model application of Protein module, using Amber10: EHT 
forcefield with a Reaction Field (R-Field). A model with better RMSD and contact energy 
was chosen. 
 
Docking: Docking of IMPDH2 and ANKRD9 was conducted with the Dock application of 
the Compute module in MOE. A number of docking configurations called poses were 
generated and scored. The score was calculated as a combination of free energy of binding 
including, among others contributions, solvation and entropy terms, and targeted regions 
interaction score that was calculated as a number of heavy atoms from the conserved regions 
of 6 sites in protein ANKRD9 contacting heavy atoms of protein IMPDH2.  
 
siRNA knockdown of ANKRD9—siGENOME SMART pool constructs against human 
ANKRD9 (Catalog number M-015551-01-0005) was used in HEK293A cells. Wet-reverse 
transfection was performed as follows: Cells were grown to ~60% confluency in complete 
medium without antibiotics. DharmaFECT at 2.5% (Cat. T-2001-002, Dharmacon) and 





for 30 minutes. 1.37x105 cells/mL of HEK293A cells were then added and mixed with 
siRNA plus DharmaFECT and incubated at 37 degrees for 60 hrs. Complete medium without 
antibiotics was added for 12 hrs for a total of 72 hours incubation. Cells were then processed 
for RT-qPCR and immunostaining for IMPDH2 rod formation.   
 
Real-time quantitative PCR (RT-qPCR)—RNA isolation and mRNA level quantitation were 
performed as previously described (83). RNA isolation was done with the RNAeasy kit 
(Qiagen), cDNA was generated and RT-PCR was done with the One-Step SYBR green kit 
(Applied Biosystems) on an ABI 7500 Sequence Detection System (Applied Biosystems). 
S18 was used for normalization for Ct analysis. Primers used in qPCR are as follows: S18 
forward: 5’-TTCTGG-CCAACGGTCTAGACAAC-3’; S18 reverse: 5’-
CCAGTGGTCTTGGTGTGCTGA-3’; ANKRD9 forward: 5’-CTGGTCACCGCCATCTCT-
3’ 
ANKRD9 reverse: 5’-CTAGCCTTTGCCAGT-GAGGT-3’ 
 
Co-Immunoprecipitation and Western Blotting— HeLa cells were transfected with FLAG-
tagged ANKRD9 and lysed with 1X RIPA buffer in PBS. Lysates were cleared with 
centrifugation at 10,000 RPM for 10 minutes. Supernatants were used in western blotting and 
co-immunoprecipitation. For the latter 15 L Anti-FLAG M2 resin (catalog number A2220, 
Millipore-Sigma) was washed with PBS then 500 L lysate was loaded onto resin via batch 
purification and incubated overnight with rotation. Resin was washed twice with PBS then 
incubated with 60 L of 2 mg/mL of FLAG peptide (catalog number F4799, Millipore-





Samples from input, unbound, wash an elution were taken to be analyzed. For western 
blotting the following antibody dilutions were used:  Mouse Anti-FLAG, dilution factor 
1:10,000, Rabbit anti-IMPDH2, dilution factor 1:10,000, Rabbit anti-CTPS2, dilution factor 
1:10,000, Mouse anti-Beta Actin, dilution factor 1:10,000 Catalog number NB600-501, 
purchased from Novus. Standard gel running and transfer methods were used, membranes 
were blocked for 1hr in 5% milk in PBS at RT and incubated with primary antibody in 1% 
milk in PBS-T. Membranes were washed the next day in PBS-T and incubated with HRP-






























Chapter 3: Conclusions and future directions 
Section 3.1: Summary and conclusions 


















Chapter 3: Conclusions and future directions 
Section 3.1: Summary and conclusions 
Metabolic state governs transition between ANKRD9 rods and vesicles 
We have shown that ANKRD9 has two distinct cellular forms whose transition is 
mediated by cells metabolic state. The switch between two forms involves depletion of 
nutrients: incubating cells for 48 hours in 0.1 % FBS converted the majority of ANKRD9 
from being associated with vesicles to forming rod structures. These rods  co-localize with 
IMPDH2, a known rod assembly enzyme that catalyzes the rate-limiting step of guanine 
nucleotide biosynthesis. We have also shown that the guanosine metabolite rapidly reverts 
ANKRD9 to vesicles under otherwise nutrient deprived conditions. That guanosine converts 
rods back to vesicles suggests that ANKRD9 and IMPDH2 are regulated by similar factors 
and that perhaps GTP can directly bind ANKRD9. This hypothesis is further supported by 
the presence of nucleotide binding pocket predicted in our ANKRD9 model.  Effect of 
metabolites on ANKRD9 behavior comes hand-in-hand with the first ANKRD9 report where 
a fasting-refeeding model increased mRNA levels of ANKRD9. Taken together, the 
available data strongly suggest that the dynamic nature of ANKRD9 is due to metabolic state 
of a cell.  
 
ANKRD9 stabilizes IMPDH2 rods 
  ANKRD9 rods formed under nutrient deprivation fully co-localize with IMPDH2 
rods but not with CTPS2, which suggest a specific role of ANKRD9 in IMPDH2-dependent 
pathways.  In addition, ANKRD9 rods co-localize specifically with inhibited IMPDH2 rods; 





ANKRD9 overexpression and rod number decreases. In addition, ANKRD9 knockdown 
increases IMPDH2 levels but lowers the formation of rods upon nutrient deprivation. These 
results suggest that ANKRD9 presence rather than IMPDH2 abundance is a determining 
factor for formation of IMPDH2 rods under condition of nutrient depletion. In contrast, under 
basal conditions ANKRD9 overexpression lowers IMPDH2 levels in agreement with a 
previous report suggesting that ANKRD9 is a part of a ubiquitin ligase complex that 
specifically targets IMPDH2. In other words, there must be a delicate balance between 
having enough ANKRD9 available to stabilize IMPDH2 rods under particular metabolic 
conditions but not too much ANKRD9 as it lowers IMPDH2 levels.  
 
Section 3.2 Future Directions 
Guanosine control of ANKRD9 cellular forms 
Guanosine reversal and a predicted nucleotide binding pocket in ANKRD9 (our data) 
suggest that ANKRD9 rods may be controlled by nucleotide metabolism. To this end, 
mutagenizing residues in the predicted binding pocket may help to determine whether 
ANKRD9 binds GTP as a prerequisite to rod dispersal and return to vesicles. The residues 
we have mutated, a conserved CysCys motif, influence both rod formation and interactions 
with IMPDH2.  Identifying mutants that allow ANKRD9 to form guanosine-insensitive rods 
would help to further investigate ANKRD9 function and mechanism.  
In addition, we have noticed that IMPDH2 residues that are predicted to interact with 
the CysCys motif of ANKRD9 are disordered in the crystal structure of IMPDH2 when the 
latter has bound GDP versus GTP. This suggests that GTP binding may indeed critically 





to vesicles. Future work on the mechanism of this process would be accelerated by having 
structures  of ANKRD9 and ANKRD9/IMPDH2 complex, as well as by direct measurements 
of nucleotide binding to purified ANKRD9 and its complex with IMPDH2.  Additionally, 
visualizing ANKRD9-dependent rod formation with electron microscopy would help to 
clarify the significant scale discrepancy between the rods formed by purified IMPDH2 
(which are typically 200-300 nanometers) to those seen in microscopy in cells (3-5 microns).  
 
Copper relation and in vivo ANKRD9 studies 
In our laboratory, initial studies into ANKRD9 came from its discovery as a novel 
copper regulator whose knockdown specifically and significantly increased copper levels. 
This finding was interesting, because in the literature ANKRD9 was reported as a regulator 
of fat metabolism and the link between copper and fat balance has recently emerged. 
Characterization of ANKRD9 knockout mice (available through KOMP consortium; 
http://www.informatics.jax.org/allele/MGI:4419197) would further these studies and may 
provide better understanding of how multiple roles of ANKRD9 are interconnected. 
ANKRD9-/- mice are viable with deceased body fat and increased lean body mass which is 
in line with the initial report on ANKRD9 having a role in lipid metabolism. Analysis of 
mouse metabolism during development would help clarify ANKRD9’s role in both copper 
metabolism and lipid homeostasis. Also, because of the copper phenotype found in cells it is 
possible that older ANKRD9-/-  mice may develop pathologies related to copper overload . 
Lastly, primary cells from these knockout mice could be used for IMPDH2 studies to 






The above studies would give structural and in vivo data supporting the determined 
role of ANKRD9 in IMPDH2 abundance and macroassembly and the earlier determined role 
of ANKRD9 in copper metabolism. This would be intriguing as it would show two separate 



































Section 1.1: Glutamine modulates ANKRD9 transition to rods 
















Section 1.1: Glutamine modulates ANKRD9 transition to rods 
Previous studies of factors that trigger formation of IMPDH2 rods have shown that 
glutamine deprivation, whereby glutamate is broken down into -ketoglutarate and ammonia 
by glutamate dehydrogenase (50,66,84), causes rod formation (48). Interestingly, this 
phenotype was suppressed with low FBS levels in growth medium. These results suggest that 
metabolic state indeed governs the transition to rods, even in IMPDH2. We therefore tested 
whether ANKRD9 responded to media not containing glutamine under both 10% and 0.1% 
FBS conditions. Surprisingly, ANKRD9/IMPDH2 rods did not form under 0.1% FBS with 
DMEM that did not contain glutamine for 48 hours. These results point to a potential role for 
glutamine in the transition of ANKRD9 from vesicles to rods as well as a possible 
explanation as to why the cysteine mutants do not form vesicles. Cysteines can be oxidized 
or reduced depending on the redox state of the cell where glutamine plays a significant role 
in glutathione metabolism; without glutamine the cell can enter an oxidized state from 
lowered production of glutathione (39,50). This suggests that the tandem cysteine residues in 







Figure 17: Glutamine prevents rod formation under nutrient limiting conditions. HeLa cells 
were transfected with FLAG-ANKRD9 in glutamine free media then placed in 0.1% FBS for 
48 hours and stained for FLAG and IMPDH2. As previously reported, IMPDH2 forms rods 


















Section 1.2: ANRKD9 co-localizes with the ERGIC53 marker 
The previous report from our laboratory identified ANKRD9 as a possible regulator 
of copper metabolism (37) as well as normal Golgi morphology (unpublished result). An 
earlier report also suggested that under basal condition ANKRD9 is targeted to vesicles (40). 
To better understand localization and function of ANKRD9 under basal conditions we 
carried out co-localization studies with various organelle markers. Markers tried included 
TGN-46 (ab16049, abcam), Golgin 97 (ab84340, abcam), LAMP1 for lysosomes (Rat anti-
LAMP1 was used but was inconclusive, ab108597, Abcam) and ERGIC53 (sc-32442 Santa 
Cruz).  These experiments revealed that the ANKRD9 vesicular form co-localizes with 
ERGIC53 (Figure 18) and may alter this compartments state. ERGIC53 marks an ER-Golgi 
compartment where membrane budding and vesicle fusion constantly takes place.  Further 
studies examined outer coat protein Sec31 where a ‘neighboring’ effect (not colocalized but 
next to each other) occurred with ANKRD9 vesicles; here ANKRD9 does not co-localize 
with COPII vesicles. Sec31 usually pairs with Sec13 but staining with this antibody was 
inconclusive. These results suggest that ANKRD9 may be involved with trafficking and 














Figure 18: ANRKD9 co-localizes with ERGIC53 and neighbors Sec31(a) HeLa cells were 
transfected with FLAG-ANKRD9 under basal conditions (10% FBS) then immunostained for 
FLAG and ERGIC53 (b) HeLa cells were transfected with FLAG-ANKRD9 and stained for 
FLAG and Sec31. Lower panel is a close up view of the neighboring effect of ANKRD9 and 
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